ARGX (argenx SE) FFO


ARGX argenx SE ARGX
80 GF Score
Price $885.80
GF Value $1,372.75
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is argenx SE FFO?

FFO (Funds from operations) only applies to REITs.

ARGX
80GF Score
argenx SE ARGX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is argenx SE (ARGX) Overvalued in 2026?

Based on GuruFocus' analysis, argenx SE stock appears to be undervalued. The current stock price of $885.80 is trading 35.5% below its estimated GF Value™ of $1,372.75. GuruFocus considers argenx SE to be Significantly Undervalued.

Key valuation signals for ARGX:

  • FFO:
  • GF Value™: $1,372.75 vs. price of $885.80 (35.5% below fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the ARGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

argenx SE Business Description

Address Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
80GF Score

Get the complete analysis for ARGX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$885.80
Price
$1,372.75
GF Value